AbCellera Biologics Inc vs ConocoPhillips — how do they compare? AbCellera Biologics Inc trades at $9.06 (market cap $2.99B), while ConocoPhillips trades at $124.95 (market cap $151.27B). The key difference: ConocoPhillips is far larger — about 50.6× AbCellera Biologics Inc's market cap, and ConocoPhillips pays a 2.67% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | COP | |
|---|---|---|
Market Cap | $2.99B | $151.27B |
Sector | Health | Energy |
52-Week High | $9.76 | $133.80 |
52-Week Low | $2.78 | $85.66 |
Enterprise Value | $2.58B | $166.87B |
Dividend Yield | — | 2.67% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →